Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/75728
Title: Prenatal choline supplementation improves biomarkers of maternal docosahexaenoic acid (DHA) status among pregnant participants consuming supplemental DHA: a randomized controlled trial
Authors: Kevin C. Klatt
Melissa Q. McDougall
Olga V. Malysheva
Siraphat Taesuwan
Aura Alex P. Loinard-González
Julie E.H. Nevins
Kara Beckman
Ruchika Bhawal
Elizabeth Anderson
Sheng Zhang
Erica Bender
Kristina H. Jackson
D. Janette King
Roger A. Dyer
Srisatish Devapatla
Ramesh Vidavalur
J. Thomas Brenna
Marie A. Caudill
Authors: Kevin C. Klatt
Melissa Q. McDougall
Olga V. Malysheva
Siraphat Taesuwan
Aura Alex P. Loinard-González
Julie E.H. Nevins
Kara Beckman
Ruchika Bhawal
Elizabeth Anderson
Sheng Zhang
Erica Bender
Kristina H. Jackson
D. Janette King
Roger A. Dyer
Srisatish Devapatla
Ramesh Vidavalur
J. Thomas Brenna
Marie A. Caudill
Keywords: Medicine;Nursing
Issue Date: 2-Sep-2022
Abstract: BACKGROUND: Dietary methyl donors (e.g., choline) support the activity of the phosphatidylethanolamine N-methyltransferase (PEMT) pathway, which generates phosphatidylcholine (PC) molecules enriched in DHA that are exported from the liver and made available to extrahepatic tissues. OBJECTIVES: This study investigated the effect of prenatal choline supplementation on biomarkers of DHA status among pregnant participants consuming supplemental DHA. METHODS: Pregnant participants (n = 30) were randomly assigned to receive supplemental choline intakes of 550 mg/d [500 mg/d d0-choline + 50 mg/d deuterium-labeled choline (d9-choline); intervention] or 25 mg/d (25 mg/d d9-choline; control) from gestational week (GW) 12-16 until delivery. All participants received a daily 200-mg DHA supplement and consumed self-selected diets. Fasting blood samples were obtained at baseline, GW 20-24, and GW 28-32; maternal/cord blood was obtained at delivery. Mixed-effects linear models were used to assess the impact of prenatal choline supplementation on maternal and newborn DHA status. RESULTS: Choline supplementation (550 vs. 25 mg/d) did not achieve a statistically significant intervention × time interaction for RBC PC-DHA (P = 0.11); a significant interaction was observed for plasma PC-DHA and RBC total DHA, with choline supplementation yielding higher levels (+32-38% and +8-11%, respectively) at GW 28-32 (P < 0.05) and delivery (P < 0.005). A main effect of choline supplementation on plasma total DHA was also observed (P = 0.018); its interaction with time was not significant (P = 0.068). Compared with controls, the intervention group exhibited higher (P = 0.007; main effect) plasma enrichment of d3-PC (d3-PC/total PC). Moreover, the ratio of d3-PC to d9-PC was higher (+50-67%; P < 0.001) in the choline intervention arm (vs. control) at GW 20-24, GW 28-32, and delivery. CONCLUSIONS: Prenatal choline supplementation improves hepatic DHA export and biomarkers of DHA status by bolstering methyl group supply for PEMT activity among pregnant participants consuming supplemental DHA. This trial is registered at www.clinicaltrials.gov as NCT03194659.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85137138654&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/75728
ISSN: 19383207
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.